SCHEMBL1565628

SCHEMBL1565628

CCCCCC(Oc1ccc(F)cc1)C(=O)Nc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ NPC1 O15118 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.52
▸ LMNA P02545 1/20 0.51
▸ MAPT P10636 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ HSPA5 P11021 2/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ FFAR2 O15552 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1564907 0.97 TP53 (0.55) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1565568 0.90 NPC1 (0.55) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1565298 0.87 NPC1 (0.56) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1565403 0.86 LMNA (0.50) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1565317 0.85 LMNA (0.56) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL1564841 0.84 CYP1A2 (0.55) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1566465 0.84 CYP1A2 (0.55) TP53SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL1564978 0.83 MEN1 (0.55) LMNAMEN1KMT2APOLB
SCHEMBL1565615 0.83 LMNA (0.49) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL1565421 0.82 HSPA5 (0.48) TP53SMN1; SMN2NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US claimed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP claimed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US disclosed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK TP53 4532/4885SMN1; SMN2 3951/4885NPC1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback